Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are overlapping neurodegenerative disorders. ALS is more commonly seen in men than women and the same may be the case for FTD. Preclinical models demonstrating sex-specific vulnerability may help to understand female resistance to ALS-FTD and thereby identify routes to therapy. We previously characterised a TDP-43Q331K knock-in mouse, which demonstrated behavioural phenotypes reminiscent of ALS-FTD in males. Here we present our behavioural observations of female TDP-43Q331K mutants. Female TDP-43Q331K knock-in mice displayed increased weight relative to wild-type and increased food intake at 20 months of age, much later than previously observed in male mutants. Spontaneous digging behaviour was initially normal and only declined in mutants in the second year of life. Gait analysis using Catwalk (https://www.noldus.com/catwalk-xt) found significant deficits in the second year of life, while nocturnal running behaviour was attenuated from ~ 250 days of life. These results indicate that while female TDP-43Q331K knock-in mice do display progressive behavioural phenotypes, these are less severe than we previously noted in male mutants. Further studies of male and female TDP-43Q331K knock-in mice may help to unravel the mechanisms underlying sex-specific vulnerability in ALS-FTD.
Subject terms: Amyotrophic lateral sclerosis, Dementia, Neuroscience, Diseases, Medical research, Neurology
Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative disorders with shared clinical, neuropathological and genetic features, indicating that they lie on a continuum1–3. While pure ALS is characterised by motor impairment, including weakness, FTD is defined by cognitive and behavioural dysfunction. A greater understanding of the mechanisms driving neurodegeneration is needed if we are to develop therapies for these devastating conditions.
Interestingly, ALS has long been recognised to disproportionately affect males. Both the incidence and prevalence of ALS are greater in men than in women and men also have a younger age of onset4–6. There are also phenotypic differences between the sexes, with a predominance of limb onset ALS in men and bulbar onset in women4,6. Epidemiological studies of FTD are fewer in number and smaller in scale, making its sex-specific effects more difficult to determine. However, a handful of studies suggest that FTD is more prevalent in males7,8, and can cause more brain hypometabolism in men when the severity of cognitive symptoms is controlled for9. These effects can, however, vary between geographical populations10–12. Bulbar onset ALS together with cognitive impairment specifically shows an overwhelmingly male predominance13. Taken together, these observations indicate an important but undefined role for biological sex in dictating the specific phenotype as well as the risk of developing diseases of the ALS-FTD spectrum.
Almost all patients with ALS, and 50% of all FTD cases, are characterised neuropathologically by nuclear clearing and cytoplasmic mislocalisation of the 43-kDa transactive response DNA-binding protein (TDP-43)14,15. Over 50 disease-associated mutations have been found in TARDBP, the gene encoding TDP-43, which account for ~ 5% of fALS, < 1% of sALS, and rare familial cases of FTD16–19. The majority of these mutations are clustered in the glycine-rich C-terminal domain20 and, interestingly, some show greater penetrance in men than women21. Although the roles of TDP-43 in disease development are elusive, the use of preclinical models that recapitulate aspects of human disease have helped to define key underlying mechanisms. While transgenic approaches may be confounded by artefacts caused by spatiotemporal patterns and levels of expression that do not faithfully recapitulate the normal biology of a protein, recently developed knock-in models that manipulate endogenous alleles are more likely to accurately represent the human condition22. We recently characterised a TDP-43Q331K knock-in mouse model of ALS-FTD harbouring only a human equivalent missense mutation in the endogenous murine Tardbp gene23. In our analysis of breeding ratios, we found that while female TDP-43Q331K knock-in mutants were present at Mendelian ratios, male mutants were under-represented. This suggested that males were more susceptible to deleterious effects of the TDP-43Q331K mutation23. We subsequently focussed our attention on male mice, finding that male mutants displayed FTD-like deficits23, including executive dysfunction, weight gain due to hyperphagia24, and reduced digging behaviour suggestive of apathy25. However, whether similar phenotypes occurred in female mutants and whether these are attenuated, as they are in women compared to men, was not determined.
Here, we present results from a longitudinal study to investigate behaviour in female homozygous mutant (TDP-43Q331K/Q331K) knock-in mice and wild-type littermates. Given the increased incidence and severity of ALS-FTD in men4–7, and the increased penetrance of TARDBP mutations in males21, we tested the hypothesis that female sex attenuates disease caused by mutant TDP-43Q331K.
Results
Weight gain and age-dependent increase in food intake in female mutant mice
We previously showed that male TDP-43Q331K/Q331K mice displayed increased weight gain from 8 months of age and were also hyperphagic compared to wild-type mice23. We therefore weighed female wild-type and TDP-43Q331K/Q331K mice but found that at 8 months of age there were no significant differences in weight (23.0 ± 1.7 g and 25.7 ± 3.8 g, respectively, P = 0.9692). However, TDP-43Q331K/Q331K mice gradually gained more weight over time and were significantly heavier than wild-type mice from 13 months of age. By 20 months, wild-type mice weighed 29.5 ± 5.0 g and TDP-43Q331K/Q331K mice weighed 45.6 ± 7.7 g (P < 0.01; mixed-effects analysis) (Fig. 1a). To determine if weight gain in the TDP-43Q331K/Q331K mice could be due to hyperphagia, food intake was measured when mice were 9, 13 and 20 months old. The amount of food eaten in 72 h did not change with age and there was no significant difference between groups, although at 20 months there was a trend towards increased food intake (Fig. 1b). Wild-type and TDP-43Q331K/Q331K mice ate 12.7 ± 2.3 g and 12.3 ± 2.2 g of food at 9 months of age (P = 0.9801), 12.2 ± 2.3 g and 11.8 ± 1.6 g of food at 13 months of age (P = 0.9633) and 11.4 g ± 1.5 g and 13.9 ± 2.8 g at 20 months (P = 0.0601 two-way ANOVA), respectively.
Age-dependent deficits in marble burying behaviour in mutant females
A subset of male TDP-43Q331K/Q331K mice were previously found to display reduced spontaneous digging as determined by the marble burying assay from as early as 5 months of age23. This may reflect apathy or reduced motivation, both of which are features of FTD25. We therefore examined marble burying behaviour in female wild-type and TDP-43Q331K/Q331K mice from 8 to 20 months of age but found no significant differences between genotypes at any given age although there was a trend towards reduced digging from 14 months onwards (Fig. 1c). At 9 months of age, wild-type mice buried 8.5 ± 1.4 marbles and TDP-43Q331K/Q331K mice buried 8.9 ± 0.7 marbles (P = 0.9966), whereas at 14 months wild-type mice buried 8.4 ± 1.2 marbles and TDP-43Q331K/Q331K mice buried 6.2 ± 2.9 marbles (P = 0.0495). When mice reached 20 months of age wild-type mice buried 7.75 ± 1.6 marbles and TDP-43Q331K/Q331K mice buried 6.4 ± 2.7 marbles (P = 0.5513, mixed-effects analysis). These results indicate that innate exploratory digging behaviours are largely intact in female mutant mice, although they may be affected in older age.
Gait deficits in aged mutant females
Our previous study showed that male TDP-43Q331K/Q331K mice have reduced Rotarod performance from ~ 6 months of age, which was likely due to increased body weight rather than impaired motor coordination23. To test for motor coordination in female mice, we carried out detailed gait analysis using the Catwalk gait analysis system (Noldus, https://www.noldus.com/catwalk-xt). TDP-43Q331K/Q331K mice had normal hindlimb base of support (BOS, the distance between the hind paws during the step cycle) from 8 to 14 months of age, but significantly wider hindlimb BOS at 20 months of age, when compared to wild-type mice (26.9 ± 5.3 mm and 23.5 ± 2.6 mm, respectively; overall P < 0.05, two-way ANOVA) (Fig. 2a). While this could be due to impaired motor coordination it could also be explained by the increased body weight.
TDP-43Q331K/Q331K mice also showed decreased hindlimb swing time (time between successive paw placements) and increased swing speed (average speed of paw travelling during the swing phase). The hindlimb swing time and swing speed of wild-type mice at 20 months were 0.09 ± 0.01 s and 0.65 ± 0.12 m/s, respectively, and were 0.07 ± 0.01 s and 0.83 ± 0.16 m/s for TDP-43Q331K/Q331K mice. This suggests that TDP-43Q331K/Q331K mice walk faster than wild-type mice (Fig. 2b, c). However, the overall duration of the runs and hindlimb stride length showed no significant difference between the two groups at 20 months of age (data not shown). Together with swing speed and time, these results suggest that TDP-43Q331K/Q331K mice take faster steps than wild-type mice.
Under normal conditions mice walk in a diagonal stepping pattern with only two diagonally opposed paws on the surface at any one time26. An increase in the percentage of time spent on 3 or 4 paws indicates instability whilst walking. Female wild-type mice spent the majority of their time on diagonal paws, and relatively little time on 3 and 4 paws from 10 to 20 months of age (Fig. 2d–f). In contrast, TDP-43Q331K/Q331K mice spent significantly more time on 3 and 4 paws (Fig. 2 d–f). This difference was most pronounced at 20 months of age, by which time wild-type mice were spending 71.4 ± 8.8% of time on diagonal paws and 5.04 ± 4.1% of time on 4 paws, whereas mutants spent 58.1 ± 8.1% of time on diagonal paws and 14.1 ± 5.6% of time on 4 paws. These changes indicate that TDP-43Q331K/Q331K mice stand for longer durations of the step cycle and may develop a less steady gait with age.
Reduced running in mutant mice
To gain further insight into the motor performance of female TDP-43Q331K/Q331K mice we measured voluntary wheel running, an assay that can be performed without disruption to the normal murine diurnal rhythm in a minimally stressful environment27. Behaviour was monitored daily in mice that had unlimited access to a running wheel, which was linked to a sensor to measure time spent running, total distance run, and speed. As they aged, both wild-type and TDP-43Q331K/Q331K mice showed a progressive decline in total time and distance run per night, but this deterioration was more marked in mutants (Fig. 3a, b). Wild-type mice had a decrease from 286 ± 102 to 109 ± 56 min of running per night and mutants had a decrease from 252 ± 107 to 33 ± 30 min of running per night between 8 and 20 months of age (overall P < 0.0001, two-way ANOVA). Wild-type mice retained their average speed from 250 to 600 days of age, but mutants declined over time and became significantly slower. By 20 months of age wild-type mice were running 2.2 ± 1.81 km per night at 1.12 ± 0.35 km/h, whereas TDP-43Q331K/Q331K mice were running 0.50 ± 0.61 km per night at 0.68 ± 0.38 km/h (Fig. 3c). This suggests that female TDP-43Q331K/Q331K mice have reduced physical performance compared to wild-types.
Preservation of functional motor units in mutant mice
To determine if the motor deficits in female mutants were due to neuromuscular dysfunction, we looked for evidence of denervation by measuring compound muscle action potentials (CMAP) in the hindlimbs of 12-month-old mice. However, we found no significant differences in CMAP amplitudes between wild-type and mutant females (36.5 ± 5.4 mV and 39.2 ± 8.9 mV, respectively; n = 3 per genotype; P = 0.6689, unpaired t-test) (Fig. 4). This suggests that functional motor units are preserved in mutant mice and that the motor deficits they display are not due to neuromuscular denervation. Nonetheless, a more detailed analysis with a larger sample size and at more timepoints may be of value in determining if female mutants are vulnerable to denervation.
Discussion
Epidemiological studies show that women are significantly less likely to develop ALS-FTD than men. Preclinical models of ALS-FTD that recapitulate this sex difference could help to understand the reasons for the protection conferred by female sex, which may in turn help towards developing therapies. In this study we found that female TDP-43Q331K knock-in mice develop motor and behavioural deficits similar to those previously observed in male mutants, but that these phenotypes were less severe in females (Table 1). The clearest indicator of this was the striking weight gain seen in mutants, which occurred later in life and to a lesser extent in females than in males. Similarly, while food intake and marble burying behaviour were significantly increased and decreased respectively in male mutants, female mutants showed only trends towards such changes. The gradual increase in weight gain in both male and female TDP-43Q331K/Q331K mice may be attributable to the role of TDP-43 in fat metabolism regulated by Tbc1d128,29, which is most likely independent of oestrogen30. However, the hyperphagia observed in female mice at 20 months when oestrogen levels have dropped31 may directly result from release of the appetite stimulating gut hormone ghrelin, normally under tonic inhibition by oestradiol32. Thus, further studies of TDP-43Q331K mice promise to help unravel how female sex protects against ALS-FTD.
Table 1.
Phenotype (compared to wild-type) | Age of onset (months) | |
---|---|---|
Male23 | Female | |
Weight gain | 8 | 13 |
Increased food intake | 9a | 20b |
Reduced marble burying | 5 | 14b |
Gait defects | 6 | 20 |
Reduced running | n/ac | 8 |
Muscle denervation | None | None |
aEarliest age at which food intake was measured.
bStatistical trend.
cAs male mice on the C57BL/6 background have low baseline levels for this task69.
Determining differences due to biological sex in other animal models of ALS/FTD is more challenging due to confounding factors such as genetic background and transgene expression levels. Nonetheless, some studies have reported sex-specific behavioural differences in mouse models of ALS and FTD. A transgenic TDP-43A315T mutant mouse shows earlier disease onset and more rapid disease progression in males than females, accompanied by reduced lifespan33, although females perform worse in spatial learning tasks34. Female TDP-43M323K knock-in mice harbouring a missense mutation in the endogenous Tardbp gene display an age-dependent decrease in grip strength, while males are normal35. Mouse models of other ALS and FTD-linked genes present a more complex picture. Males overexpressing human mutant superoxide dismutase 1 (SOD1G93A) show earlier disease onset than females36, although this is dependent on genetic background37,38. However, the opposite is observed in females harbouring an inducible D83G point mutation in murine Sod1, which demonstrate earlier impairment in Rotarod performance, though males reach end-stage sooner39. Female SOD1G37R mice also have increased maladaptive axonal arborisation compared to males, which corresponds to neuronal loss and muscular denervation40. In contrast, transgenic female mice expressing the G118V mutation in profilin1 (PFN1) reach end-stage earlier than males, although age of disease onset is unaffected by sex41. Similarly, female transgenic mice expressing a mutant form of chromosome 9 open reading frame 72 (C9ORF72), the most common known genetic cause of ALS-FTD3, have reduced body weight while male mutants are unaffected42. This suggests an intricate regulation of sex-specific behaviours in diverse animal models.
Genetic studies in humans also suggest that biological sex influences the phenotype of both ALS and FTD. Mutations in TARDBP, while rare, appear to be more penetrant in male than female patients21. Conversely, mutations in C9ORF72 have been shown to be more commonly seen in women than men with ALS43, although this difference is not observed in C9ORF72-related FTD43. Mutations in progranulin (GRN) are also more common in women43, and mutations in T-cell restricted intracellular antigen 1 (TIA1) have, to date, been found exclusively in women44. Mutations in microtubule-associated protein tau (MAPT) by contrast are not specific to either sex43.
A likely explanation for sex differences in neurodegenerative disease is the role of reproductive hormones. Oestrogens, specifically 17β-oestradiol, can exert neuroprotective effects in both males and females by signalling through oestrogen receptors, which are widely distributed in the brain45. These effects range from maintenance of cognition and response to injury, to dendritic spine maturation and adult neurogenesis46. This is in keeping with findings from patients with ALS in whom the sex differences in incidence and prevalence diminish with age4. This may well be due to the reduction in levels of oestrogen in post-menopausal women5.
The protective effects of sex hormones are not only restricted to neurons, which constitutively produce oestradiol, but also glia45. Astrocytes show sex differences in their development, number and morphology, in addition to functional characteristics like glutamate uptake and their response to cannabinoids, gonadotrophic hormones, and harmful stimuli such as environmental toxins47. Microglia, the innate immune cells of the central nervous system, develop sex-specific transcriptional differences in adulthood, although it is debated which sex develops a more pro-inflammatory phenotype48. This may contribute to sex-specific differences in ALS-FTD, given that microglia play key roles during development and ageing, express high levels of the FTD-linked gene GRN49, and have been implicated in disease pathogenesis by several mouse models of ALS50–52.
The effects of sex hormones on brain mitochondrial metabolism have also been well documented53. For example, 17β-oestradiol can transcriptionally regulate and increase the function of components of the respiratory chain while reducing oxidative stress in brain mitochondria. Cerebral expression of the oestrogen receptors ERα and ERβ is also sexually dimorphic53. Incidentally, female transgenic mutant SOD1 mice have delayed onset of mitochondrial dysfunction in the spinal cord compared to males54, possibly resulting from ERα-dependent activation of the mitochondrial unfolded protein response55. This transcriptional programme for restoration of proteostasis can also be activated by TDP-4356. Hormonal regulation may also affect disease course in ALS through regulation of the expression of a group of muscle-specific microRNAs57. The effects of progesterone and testosterone on the brain are, however, more elusive, with multiple mechanisms both conferring neuroprotection and enhancing neurodegeneration58–63.
Abundant evidence indicates sexual dimorphism in varied neurodegenerative diseases. Males have a two-fold increased risk of Parkinson’s disease, and also present with more marked non-motor symptoms compared to females64. In contrast, females are more likely to develop Alzheimer’s disease65, particularly those with the APOEε4 allele66, and women with Huntington’s disease show a faster rate of progression than men67. Our findings add to a growing body of evidence suggesting that the influence of biological sex in neurodegenerative diseases is complex, resulting not only from genetic architecture, age, epigenomic and transcriptomic factors, but also from the effects of reproductive hormones on glial and neuronal cells, and organelle function. We conclude that the TDP-43Q331K/Q331K knock-in mouse, which displays sex-specific behavioural differences, can be utilised as a tool to investigate female resistance to ALS-FTD and thereby help towards developing therapies for this disease spectrum.
Methods
Mouse model and genotyping
Mice were generated using CRISPR/Cas9 mutagenesis as described previously23 and maintained on a C57BL/6J background by crossing with wild-type animals. Animals were bred in a specific pathogen free environment and transferred to a conventional facility under a 12-h light/dark cycle. Cages (36 × 21 × 18.5 cm) were lined with fine sawdust (eco-pure flakes 6, Datesand, UK), a plastic house was placed in each cage and paper wool (Datesand, UK) was used as bedding material. All mice were singly housed due to the use of running wheels in the home cage, with food (Harlan, UK) and water available at libitum. Animals were genotyped as described previously23. All experiments were conducted in accordance with the United Kingdom Animals (Scientific Procedures) Act (1986) and the United Kingdom Animals (Scientific Procedures) Act (1986) Amendment Regulations 2012, and also reviewed and approved by the University of Sheffield Animal Welfare and Ethical Review Body (AWERB). Power calculations were determined as described previously23. All of the behavioural testing was carried out on the same cohort of female mice. One wild-type and one mutant mouse developed skin conditions at 1 year of age and were humanely culled on compassionate grounds. One wild-type and one mutant mouse lost 20% of their bodyweight nearing the 20-month time point and were culled on compassionate grounds. One additional mutant mouse was found to be unwell at 20 months of age and was culled.
Body weight and food intake
Animals were weighed weekly in the morning as previously described23. Food intake was monitored at various timepoints by weighing the food in the hopper, then re-weighing approximately 72 h later. During the 72-h period, sawdust in the cage was replaced with paper towelling to ensure any small pieces of food dropped from the top of the hopper could be included for weighing.
Marble burying
The marble burying assay was conducted as described previously23, except that different cages were used. Briefly, all testing was conducted in the morning and blind to genotype in cages of size 33 × 21 × 19 cm (Tecniplast) with fresh sawdust (Datesand, grade 6) placed to a height of ~ 8 cm. Ten glass marbles (1 cm) were placed evenly across the bedding. A single mouse was placed in each of the cages, the lids replaced, and left undisturbed for 30 min under white light. Mice were then removed, and the number of marbles buried by at least two thirds was scored.
Catwalk gait analysis
The Catwalk gait analysis system 7.1 (Noldus Information Technology B.V., Netherlands, https://www.noldus.com/catwalk-xt) was used to capture gait parameters at 8, 10, 12, 14, and 20 months of age as previously described38. Mice were placed on the glass floor of the catwalk system in complete darkness and left to walk/run freely. Whenever possible, six continuous runs were recorded, with the three best runs being selected for analysis. Catwalk software 7.1 was used to label each paw print during each run and analyse the gait parameters of the mice.
Running wheel analysis
The running wheel set-up was based on an in-house protocol described previously68. Each cage contained a 37.8 cm circumference Fast Trac running wheel (LBS Biotech, UK) mounted at 25˚ below horizontal, on a 4 cm fixed post. The wheel was placed in the corner of each cage where the circumference was 5–10 mm from the edge of two perpendicular sides of the cage. A 5 × 10 mm neodymium magnet was glued to the underside of each Fast Trac wheel and a bicycle computer (Cateye Velo, Japan) with reed switch was fixed to the side of the cage. Time spent running, distance run, and average running speed were recorded daily.
Compound muscle action potential (CMAP) amplitude testing
Mice were placed under gaseous anaesthesia (1–2% isoflurane), with body temperature maintained using an electric heat pad (CWE, USA), and fur from the left hindlimb and lower back was removed. All recordings were made using a Dantec Keypoint Focus EMG System (Optima, UK) as previously described38. A grounding electrode was placed in the base of the tail (Ambu Neuroline, UK), and ring recording electrodes were placed circumferentially around the distal hindlimb muscles (Alpine Biomed, Denmark), layered with Ten20 nerve conductive paste (Pulse Medical Ltd, UK). CMAPs were acquired by applying a single, square wave electrical impulse of 0.1 ms duration to the sciatic notch using twisted pair subdermal electrodes (Ambu Neuroline, UK). The position of the subcutaneous stimulating electrodes was trialled to ensure that a response was obtained using a stimulating current of 1–2 mA. The stimulation intensity was then increased until no further increase in amplitude was seen and a supramaximal response elicited.
Statistical analyses
All data was analysed using GraphPad Prism version 8 (https://www.graphpad.com/scientific-software/prism/). Statistical significance was determined by two-way analysis of variance (ANOVA) with or without repeated measures with Sidak correction for multiple testing, mixed effects analysis, or Student’s t-test. Results having P < 0.05 were considered significant in every analysis.
Please note that this methods section was adapted from the PhD thesis of the first author, which can be found at https://etheses.whiterose.ac.uk/id/eprint/16694 re-used here under a creative commons CC BY-NC-ND 2.0 UK license (https://creativecommons.org/licenses/by-nc-nd/2.0/uk/).
Acknowledgements
We thank staff of the Babraham Institute Experimental Unit and Biological Services Unit at the University of Sheffield for technical assistance. J.S. gratefully acknowledges support from the Motor Neuron Disease Association, the Medical Research Council UK, the Lady Edith Wolfson Fellowship Fund, the van Geest Foundation, the Rosetrees Trust, Alzheimer’s Research UK, and the Psychiatry Research Trust. This work was partly funded by Motor Neuron Disease Association grants awarded to R.M. (SITraN/Apr13/983-797 and SITraN/Jul16/987-797) and to R.M. and J.W. (Mead/Jun16/900-790). J.J.P.A. is funded by a National Institute for Health Research Clinical Lectureship. J.W. was funded by a University of Sheffield PhD scholarship.
Author contributions
J.W., A.K., R.M., and J.S. designed the study. J.W., A.K. and J.J.P.A. performed the experiments and analysed the data. A.G. and J.S wrote the manuscript with contributions from all authors.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Jodie Watkins and Anshua Ghosh.
Change history
5/20/2021
A Correction to this paper has been published: 10.1038/s41598-021-90064-2
Contributor Information
Richard J. Mead, Email: r.j.mead@sheffield.ac.uk
Jemeen Sreedharan, Email: jemeen.sreedharan@kcl.ac.uk.
References
- 1.Neary D, et al. Frontal lobe dementia and motor neuron disease. J Neurol. Neurosurg. Psychiatry. 1990;53:23–32. doi: 10.1136/jnnp.53.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Ferrari R, Kapogiannis D, Huey ED, Momeni P. FTD and ALS: A tale of two diseases. Curr. Alzheimer Res. 2011;8:273–294. doi: 10.2174/156720511795563700. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Burrell JR, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388:919–931. doi: 10.1016/S0140-6736(16)00737-6. [DOI] [PubMed] [Google Scholar]
- 4.McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend. Med. 2010;7:557–570. doi: 10.1016/j.genm.2010.11.010. [DOI] [PubMed] [Google Scholar]
- 5.Manjaly ZR, et al. The sex ratio in amyotrophic lateral sclerosis: A population based study. Amyotroph. Lateral. Scler. 2010;11:439–442. doi: 10.3109/17482961003610853. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Chen L, et al. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J. Neurol. Neurosurg. Psychiatry. 2015;86:1075–1081. doi: 10.1136/jnnp-2015-310471. [DOI] [PubMed] [Google Scholar]
- 7.Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58:1615–1621. doi: 10.1212/wnl.58.11.1615. [DOI] [PubMed] [Google Scholar]
- 8.Johnson JK, et al. Frontotemporal lobar degeneration: Demographic characteristics of 353 patients. Arch. Neurol. 2005;62:925–930. doi: 10.1001/archneur.62.6.925. [DOI] [PubMed] [Google Scholar]
- 9.Perneczky R, Diehl-Schmid J, Forstl H, Drzezga A, Kurz A. Male gender is associated with greater cerebral hypometabolism in frontotemporal dementia: Evidence for sex-related cognitive reserve. Int. J. Geriatr. Psychiatry. 2007;22:1135–1140. doi: 10.1002/gps.1803. [DOI] [PubMed] [Google Scholar]
- 10.Mercy L, Hodges JR, Dawson K, Barker RA, Brayne C. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology. 2008;71:1496–1499. doi: 10.1212/01.wnl.0000334277.16896.fa. [DOI] [PubMed] [Google Scholar]
- 11.Bernardi L, et al. Epidemiology and genetics of frontotemporal dementia: A door-to-door survey in southern Italy. Neurobiol. Aging. 2012;33:2948e2910–2948e2941. doi: 10.1016/j.neurobiolaging.2012.06.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Rosso SM, et al. Frontotemporal dementia in The Netherlands: Patient characteristics and prevalence estimates from a population-based study. Brain. 2003;126:2016–2022. doi: 10.1093/brain/awg204. [DOI] [PubMed] [Google Scholar]
- 13.Portet F, Cadilhac C, Touchon J, Camu W. Cognitive impairment in motor neuron disease with bulbar onset. Amyotroph. Lateral Scler. Other Motor. Neuron Disord. 2001;2:23–29. doi: 10.1080/146608201300079382. [DOI] [PubMed] [Google Scholar]
- 14.Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–133. doi: 10.1126/science.1134108. [DOI] [PubMed] [Google Scholar]
- 15.Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602–611. doi: 10.1016/j.bbrc.2006.10.093. [DOI] [PubMed] [Google Scholar]
- 16.Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668–1672. doi: 10.1126/science.1154584. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Daoud H, et al. Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. J. Med. Genet. 2009;46:112–114. doi: 10.1136/jmg.2008.062463. [DOI] [PubMed] [Google Scholar]
- 18.Kabashi E, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008;40:572–574. doi: 10.1038/ng.132. [DOI] [PubMed] [Google Scholar]
- 19.Benajiba L, et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann. Neurol. 2009;65:470–473. doi: 10.1002/ana.21612. [DOI] [PubMed] [Google Scholar]
- 20.Buratti E. Functional significance of TDP-43 mutations in disease. Adv. Genet. 2015;91:1–53. doi: 10.1016/bs.adgen.2015.07.001. [DOI] [PubMed] [Google Scholar]
- 21.Borghero G, et al. Genetic architecture of ALS in Sardinia. Neurobiol. Aging. 2014;35:2882e2812–2882e2887. doi: 10.1016/j.neurobiolaging.2014.07.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Lutz C. Mouse models of ALS: Past, present and future. Brain Res. 2018;1693:1–10. doi: 10.1016/j.brainres.2018.03.024. [DOI] [PubMed] [Google Scholar]
- 23.White MA, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat. Neurosci. 2018;21:552–563. doi: 10.1038/s41593-018-0113-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ahmed RM, et al. Eating behavior in frontotemporal dementia: Peripheral hormones vs hypothalamic pathology. Neurology. 2015;85:1310–1317. doi: 10.1212/WNL.0000000000002018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.McKhann GM, et al. Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on frontotemporal dementia and Pick's disease. Arch. Neurol. 2001;58:1803–1809. doi: 10.1001/archneur.58.11.1803. [DOI] [PubMed] [Google Scholar]
- 26.Mendes CS, et al. Quantification of gait parameters in freely walking rodents. BMC Biol. 2015;13:50. doi: 10.1186/s12915-015-0154-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Lerman I, et al. Genetic variability in forced and voluntary endurance exercise performance in seven inbred mouse strains. J. Appl. Physiol. 2002;1985(92):2245–2255. doi: 10.1152/japplphysiol.01045.2001. [DOI] [PubMed] [Google Scholar]
- 28.Chiang PM, et al. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc. Natl. Acad. Sci. USA. 2010;107:16320–16324. doi: 10.1073/pnas.1002176107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Stallings NR, et al. TDP-43, an ALS linked protein, regulates fat deposition and glucose homeostasis. PLoS ONE. 2013;8:e71793. doi: 10.1371/journal.pone.0071793. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Hong J, Stubbins RE, Smith RR, Harvey AE, Nunez NP. Differential susceptibility to obesity between male, female and ovariectomized female mice. Nutr. J. 2009;8:11. doi: 10.1186/1475-2891-8-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Koebele SV, Bimonte-Nelson HA. Modeling menopause: The utility of rodents in translational behavioral endocrinology research. Maturitas. 2016;87:5–17. doi: 10.1016/j.maturitas.2016.01.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Clegg DJ, et al. Estradiol-dependent decrease in the orexigenic potency of ghrelin in female rats. Diabetes. 2007;56:1051–1058. doi: 10.2337/db06-0015. [DOI] [PubMed] [Google Scholar]
- 33.Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2009;106:18809–18814. doi: 10.1073/pnas.0908767106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Medina DX, Orr ME, Oddo S. Accumulation of C-terminal fragments of transactive response DNA-binding protein 43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice. Neurobiol. Aging. 2014;35:79–87. doi: 10.1016/j.neurobiolaging.2013.07.006. [DOI] [PubMed] [Google Scholar]
- 35.Fratta P, et al. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 2018 doi: 10.15252/embj.201798684. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Veldink JH, et al. Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. Neuromuscul. Disord. 2003;13:737–743. doi: 10.1016/s0960-8966(03)00104-4. [DOI] [PubMed] [Google Scholar]
- 37.Heiman-Patterson TD, et al. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 2005;236:1–7. doi: 10.1016/j.jns.2005.02.006. [DOI] [PubMed] [Google Scholar]
- 38.Mead RJ, et al. Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS) PLoS ONE. 2011;6:e23244. doi: 10.1371/journal.pone.0023244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Joyce PI, et al. A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicity. Hum. Mol. Genet. 2015;24:1883–1897. doi: 10.1093/hmg/ddu605. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Martineau E, Di Polo A, Vande Velde C, Robitaille R. Sex-specific differences in motor-unit remodeling in a mouse model of ALS. eNeuro. 2020 doi: 10.1523/ENEURO.0388-19.2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Fil D, et al. Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Hum. Mol. Genet. 2017;26:686–701. doi: 10.1093/hmg/ddw429. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Chew J, et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 2015;348:1151–1154. doi: 10.1126/science.aaa9344. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Curtis AF, et al. Sex differences in the prevalence of genetic mutations in FTD and ALS: A meta-analysis. Neurology. 2017;89:1633–1642. doi: 10.1212/WNL.0000000000004494. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Hirsch-Reinshagen V, et al. Clinical and neuropathological features of ALS/FTD with TIA1 mutations. Acta Neuropathol. Commun. 2017;5:96. doi: 10.1186/s40478-017-0493-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Arevalo MA, Azcoitia I, Garcia-Segura LM. The neuroprotective actions of oestradiol and oestrogen receptors. Nat. Rev. Neurosci. 2015;16:17–29. doi: 10.1038/nrn3856. [DOI] [PubMed] [Google Scholar]
- 46.Zarate S, Stevnsner T, Gredilla R. Role of estrogen and other sex hormones in brain aging. Neuroprotection and DNA repair. Front. Aging Neurosci. 2017;9:430. doi: 10.3389/fnagi.2017.00430. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Acaz-Fonseca E, Avila-Rodriguez M, Garcia-Segura LM, Barreto GE. Regulation of astroglia by gonadal steroid hormones under physiological and pathological conditions. Prog. Neurobiol. 2016;144:5–26. doi: 10.1016/j.pneurobio.2016.06.002. [DOI] [PubMed] [Google Scholar]
- 48.Kodama L, Gan L. Do microglial sex differences contribute to sex differences in neurodegenerative diseases? Trends Mol. Med. 2019;25:741–749. doi: 10.1016/j.molmed.2019.05.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916–919. doi: 10.1038/nature05016. [DOI] [PubMed] [Google Scholar]
- 50.Boillee S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389–1392. doi: 10.1126/science.1123511. [DOI] [PubMed] [Google Scholar]
- 51.Frakes AE, et al. Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron. 2014;81:1009–1023. doi: 10.1016/j.neuron.2014.01.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Spiller KJ, et al. Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat. Neurosci. 2018;21:329–340. doi: 10.1038/s41593-018-0083-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Gaignard P, et al. Role of sex hormones on brain mitochondrial function, with special reference to aging and neurodegenerative diseases. Front. Aging Neurosci. 2017;9:406. doi: 10.3389/fnagi.2017.00406. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Cacabelos D, et al. Early and gender-specific differences in spinal cord mitochondrial function and oxidative stress markers in a mouse model of ALS. Acta Neuropathol. Commun. 2016;4:3. doi: 10.1186/s40478-015-0271-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Riar AK, et al. Sex specific activation of the ERalpha axis of the mitochondrial UPR (UPRmt) in the G93A-SOD1 mouse model of familial ALS. Hum. Mol. Genet. 2017;26:1318–1327. doi: 10.1093/hmg/ddx049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Wang P, et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019;15:e1007947. doi: 10.1371/journal.pgen.1007947. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Pegoraro V, Merico A, Angelini C. Micro-RNAs in ALS muscle: Differences in gender, age at onset and disease duration. J. Neurol. Sci. 2017;380:58–63. doi: 10.1016/j.jns.2017.07.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Caruso A, et al. Testosterone amplifies excitotoxic damage of cultured oligodendrocytes. J. Neurochem. 2004;88:1179–1185. doi: 10.1046/j.1471-4159.2004.02284.x. [DOI] [PubMed] [Google Scholar]
- 59.Sayeed I, Wali B, Stein DG. Progesterone inhibits ischemic brain injury in a rat model of permanent middle cerebral artery occlusion. Restor. Neurol. Neurosci. 2007;25:151–159. [PubMed] [Google Scholar]
- 60.Carroll JC, Rosario ER, Pike CJ. Progesterone blocks estrogen neuroprotection from kainate in middle-aged female rats. Neurosci. Lett. 2008;445:229–232. doi: 10.1016/j.neulet.2008.09.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Fargo KN, Foecking EM, Jones KJ, Sengelaub DR. Neuroprotective actions of androgens on motoneurons. Front. Neuroendocrinol. 2009;30:130–141. doi: 10.1016/j.yfrne.2009.04.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Wilson RE, Coons KD, Sengelaub DR. Neuroprotective effects of testosterone on dendritic morphology following partial motoneuron depletion: efficacy in female rats. Neurosci. Lett. 2009;465:123–127. doi: 10.1016/j.neulet.2009.09.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Blasco H, et al. Amyotrophic lateral sclerosis: A hormonal condition? Amyotroph. Lateral. Scler. 2012;13:585–588. doi: 10.3109/17482968.2012.706303. [DOI] [PubMed] [Google Scholar]
- 64.Van Den Eeden SK, et al. Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 2003;157:1015–1022. doi: 10.1093/aje/kwg068. [DOI] [PubMed] [Google Scholar]
- 65.Li R, Singh M. Sex differences in cognitive impairment and Alzheimer's disease. Front. Neuroendocrinol. 2014;35:385–403. doi: 10.1016/j.yfrne.2014.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Safieh M, Korczyn AD, Michaelson DM. ApoE4: An emerging therapeutic target for Alzheimer's disease. BMC Med. 2019;17:64. doi: 10.1186/s12916-019-1299-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Zielonka D, et al. The influence of gender on phenotype and disease progression in patients with Huntington's disease. Parkinsonism Relat. Disord. 2013;19:192–197. doi: 10.1016/j.parkreldis.2012.09.012. [DOI] [PubMed] [Google Scholar]
- 68.Bennett EJ, Mead RJ, Azzouz M, Shaw PJ, Grierson AJ. Early detection of motor dysfunction in the SOD1G93A mouse model of Amyotrophic Lateral Sclerosis (ALS) using home cage running wheels. PLoS ONE. 2014;9:e107918. doi: 10.1371/journal.pone.0107918. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.De Bono JP, Adlam D, Paterson DJ, Channon KM. Novel quantitative phenotypes of exercise training in mouse models. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006;290:R926–934. doi: 10.1152/ajpregu.00694.2005. [DOI] [PubMed] [Google Scholar]